Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.
- 1 April 1994
- journal article
- abstracts
- Published by Wolters Kluwer Health in Hypertension
- Vol. 23 (4) , 439-449
- https://doi.org/10.1161/01.hyp.23.4.439
Abstract
We examined the dose-related effects of angiotensin-converting enzyme inhibitors on circulating and tissue levels of angiotensin and bradykinin peptides by administering perindopril or lisinopril to rats in drinking water for 7 days. A reduction in the ratio of plasma angiotensin II (Ang II) to Ang I was seen for 0.006 mg/kg per day perindopril, with an increase in plasma renin and Ang I at 0.017 mg/kg per day. Plasma Ang II levels did not decrease until 1.4 mg/kg per day perindopril, at which dose plasma Ang I levels reached a plateau of an approximate 25-fold increase. The effects of perindopril on Ang II and Ang I levels in heart, lung, aorta, and brown adipose tissue were parallel to those observed for plasma. By contrast, renal Ang I levels did not increase, and renal Ang II levels decreased by 40% at 0.017 mg/kg per day, the same threshold seen for the increase in plasma renin. Perindopril increased circulating bradykinin-(1-9) levels approximately eightfold, with a threshold dose of 0.052 mg/kg per day, and increased bradykinin-(1-9) levels in kidney, heart, and lung in parallel with the changes observed for plasma. By contrast, aortic and brown adipose tissue bradykinin-(1-9) and bradykinin-(1-7) levels increased severalfold for perindopril doses as low as 0.006 mg/kg per day. Lisinopril also increased aortic bradykinin-(1-9) and bradykinin-(1-7) levels at doses below the threshold for the decrease in the ratio of Ang II to Ang I. These data indicate that renal Ang II levels and vascular bradykinin-(1-9) levels respond to low doses of converting enzyme inhibitor and may be important mediators of the effects of these compounds. The parallel increases in bradykinin-(1-9) and bradykinin-(1-7) levels in aorta and brown adipose tissue, at inhibitor doses below the threshold for inhibition of Ang I conversion, may result from a mechanism different from inhibition of "classic" angiotensin-converting enzyme.Keywords
This publication has 47 references indexed in Scilit:
- Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril.Hypertension, 1992
- Kinins mediate the antiproliferative effect of ramipril in rat carotid arteryBiochemical and Biophysical Research Communications, 1992
- Peripheral hemodynamic effects of captopril in patients with congestive heart failureAmerican Heart Journal, 1989
- Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-aldosterone and bradykinin profile in hypertensionAmerican Heart Journal, 1983
- Renal hemodynamics and renal kinins after angiotensin-converting enzyme inhibitionKidney International, 1981
- The antihypertensive effect of captopril. Evidence for an influence of kinins.Hypertension, 1980
- Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension.Hypertension, 1980
- The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man.Hypertension, 1979
- Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.Hypertension, 1979
- Accentuated Vascular and Endocrine Response to Sq 20881 in HypertensionNew England Journal of Medicine, 1977